Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 8Leukemia, Myeloid, Acute 6Breast Neoplasms 6Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Skin Neoplasms 3Mesothelioma, Malignant 3Lymphoma, Non-Hodgkin 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Stomach Neoplasms 2Sarcoma 2Recurrence 2Rectal Neoplasms 2Pleural Effusion, Malignant 2Neuroblastoma 2Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Leukemia, Myeloid 2Leukemia 2Head and Neck Neoplasms 2Glioblastoma 2Esophageal Neoplasms 2Carcinoma, Merkel Cell 2Urinary Bladder Neoplasms 1Turcot syndrome 1

Interventions

fludarabine 1Interleukin-2 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Select Advanced Solid Tumors × Interleukin-2 × Clear all
NCT06598371 2026-05-20

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
141 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡